- Home
- TLSI vs BGX Comparison
TLSI vs BGX Comparison
Compare TLSI & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- BGX
- Stock Information
- Founded
- TLSI 2010
- BGX 2010
- Country
- TLSI United States
- BGX United States
- Employees
- TLSI N/A
- BGX N/A
- Industry
- TLSI Medical Specialities
- BGX Trusts Except Educational Religious and Charitable
- Sector
- TLSI Health Care
- BGX Finance
- Exchange
- TLSI Nasdaq
- BGX Nasdaq
- Market Cap
- TLSI 166.8M
- BGX 162.9M
- IPO Year
- TLSI N/A
- BGX N/A
- Fundamental
- Price
- TLSI $4.99
- BGX $12.91
- Analyst Decision
- TLSI Strong Buy
- BGX
- Analyst Count
- TLSI 2
- BGX 0
- Target Price
- TLSI $14.00
- BGX N/A
- AVG Volume (30 Days)
- TLSI 71.8K
- BGX 67.9K
- Earning Date
- TLSI 08-14-2024
- BGX 01-01-0001
- Dividend Yield
- TLSI N/A
- BGX 10.34%
- EPS Growth
- TLSI N/A
- BGX N/A
- EPS
- TLSI N/A
- BGX N/A
- Revenue
- TLSI $24,736,000.00
- BGX N/A
- Revenue This Year
- TLSI $61.24
- BGX N/A
- Revenue Next Year
- TLSI $47.32
- BGX N/A
- P/E Ratio
- TLSI N/A
- BGX N/A
- Revenue Growth
- TLSI 67.75
- BGX N/A
- 52 Week Low
- TLSI $3.32
- BGX $10.69
- 52 Week High
- TLSI $10.42
- BGX $12.44
- Technical
- Relative Strength Index (RSI)
- TLSI 38.25
- BGX 55.79
- Support Level
- TLSI $4.80
- BGX $12.63
- Resistance Level
- TLSI $5.47
- BGX $13.07
- Average True Range (ATR)
- TLSI 0.33
- BGX 0.15
- MACD
- TLSI -0.04
- BGX -0.00
- Stochastic Oscillator
- TLSI 19.39
- BGX 63.64
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About BGX Blackstone Long Short Credit Income Fund
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategy in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first- and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.